Skip to main content

Advertisement

SpringerLink
Log in

Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors

  • Sarcoma
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Neoadjuvant imatinib is used to downstage surgery for large and/or unfavorably located gastric gastrointestinal stromal tumors (GISTs), but data regarding minimally invasive surgery (MIS) after neoadjuvant imatinib are limited.

Patients and Methods

We analyzed patients undergoing resection of nonmetastatic primary gastric GISTs larger than or equal to 4.5 cm in diameter at our institution between 2009 and 2020, as no tumors below this size received neoadjuvant imatinib.

Results

We identified 71 patients, 43 of whom (61%) received neoadjuvant imatinib. Patients receiving neoadjuvant imatinib had larger tumors at diagnosis [median diameter 8.6 cm (range 4.5–25 cm) versus 5.9 cm (range 4.5–11 cm), p < 0.01]. After a median 7.2 months of imatinib, tumors shrank by a median 34% in diameter, such that there was no longer a significant size difference at time of surgery between groups (median 6.3 cm versus 5.9 cm, p = 0.69). Of 29 patients for whom neoadjuvant imatinib was used to facilitate MIS, 21 (72%) underwent successful MIS, which accounted for 49% of the entire neoadjuvant cohort. In a multivariable regression model, smaller tumor size at time of surgery was predictive of successful MIS, but tumor location was not.

Conclusions

Neoadjuvant imatinib caused significant tumor shrinkage, and MIS was successful in 72% of cases for which neoadjuvant imatinib was intended to facilitate it. Smaller tumor size at time of surgery, but not tumor location, was associated with successful MIS, which may help inform patient selection for neoadjuvant imatinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Casali PG, Le Cesne A, Poveda Velasco A, et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the Australasian gastro-intestinal trials group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. J Clin Oncol. 2015;33:4276–83.

    Article  CAS  Google Scholar 

  2. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.

    Article  CAS  Google Scholar 

  3. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72.

    Article  CAS  Google Scholar 

  4. Cavnar MJ, Seier K, Gonen M, et al. Prognostic factors after neoadjuvant imatinib for newly diagnosed primary gastrointestinal stromal tumor. J Gastrointest Surg 2020.

  5. Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4:e184060.

    Article  Google Scholar 

  6. Emory TS, Sobin LH, Lukes L, Lee DH, O’Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol. 1999;23:82–7.

    Article  CAS  Google Scholar 

  7. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100:162–8.

    Article  Google Scholar 

  8. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–52.

    Article  Google Scholar 

  9. Fiore M, Palassini E, Fumagalli E, et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol. 2009;35:739–45.

    Article  CAS  Google Scholar 

  10. Kurokawa Y, Yang HK, Cho H, et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer. 2017;117:25–32.

    Article  CAS  Google Scholar 

  11. Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013;20:2937–43. https://doi.org/10.1245/s10434-013-3013-7.

    Article  PubMed  Google Scholar 

  12. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.

    Article  Google Scholar 

  13. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191–2.

    Article  CAS  Google Scholar 

  14. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1 1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  Google Scholar 

  15. Fairweather M, Balachandran VP, Li GZ, et al. Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors: a 2-institutional analysis. Ann Surg. 2018;268:296–302.

    Article  Google Scholar 

  16. Kawabata K, Takahashi T, Nakajima K, et al. Laparoscopic resection of a huge gastric gastrointestinal stromal tumor after neoadjuvant chemotherapy—a case report. Gan To Kagaku Ryoho. 2020;47:670–2.

    PubMed  Google Scholar 

  17. Yoshioka S, Tazawa H, Saito A, et al. Laparoscopic resection for a large gastrointestinal stromal tumor (GIST) with diaphragm invasion following preoperative imatinib treatment: a case report. Int J Surg Case Rep. 2021;81:105727.

    Article  Google Scholar 

  18. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.

    Article  Google Scholar 

  19. Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Eur J Surg Oncol. 2014;40:420–8.

    Article  CAS  Google Scholar 

  20. Joo I, Lee JM, Lee ES, et al. Preoperative CT classification of the resectability of pancreatic cancer: interobserver agreement. Radiology. 2019;293:343–9.

    Article  Google Scholar 

  21. Mohammad WM, Martel G, Mimeault R, Fairfull-Smith RJ, Auer RC, Balaa FK. Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB (Oxford). 2012;14:291–7.

    Article  Google Scholar 

  22. Balbona J, Chen L, Malafa MP, et al. Outcomes of gastric resection in the establishment of a comprehensive oncologic robotic program. J Surg Res. 2020;252:30–6.

    Article  Google Scholar 

  23. Maggioni C, Shida A, Mancini R, Ioni L, Pernazza G. Safety profile and oncological outcomes of gastric gastrointestinal stromal tumors (GISTs) robotic resection: single center experience. Int J Med Robot. 2019;15:e2031.

    Article  Google Scholar 

  24. Winder A, Strauss DC, Jones RL, et al. Robotic surgery for gastric gastrointestinal stromal tumors: a single center case series. J Surg Oncol. 2020. https://doi.org/10.1016/j.ejso.2019.11.454.

    Article  PubMed  Google Scholar 

  25. Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27:1511–9.

    Article  CAS  Google Scholar 

  26. Poort H, van der Graaf WT, Tielen R, et al. Prevalence, impact, and correlates of severe fatigue in patients with gastrointestinal stromal tumors. J Pain Symptom Manage. 2016;52:265–71.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA

    George Z. Li MD, Mark Fairweather MD, Chandrajit P. Raut MD, MSc & Jiping Wang MD, PhD

  2. Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Mark Fairweather MD, Chandrajit P. Raut MD, MSc & Jiping Wang MD, PhD

Authors
  1. George Z. Li MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Fairweather MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chandrajit P. Raut MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiping Wang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiping Wang MD, PhD.

Ethics declarations

Disclosure

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 13 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, G.Z., Fairweather, M., Raut, C.P. et al. Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors. Ann Surg Oncol 29, 7104–7113 (2022). https://doi.org/10.1245/s10434-022-11891-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-11891-9

Search

Navigation